Palbocent 125 — Palbociclib 125 mg, 21 pcs, Incepta Pharmaceuticals
100% original product

Palbocent 125 Capsules — Palbociclib 125 mg (21 Capsules) Incepta

7894₴ 9209₴ -14%

Palbocent 125 mg (Palbociclib) is an advanced targeted anticancer therapy and a first-in-class selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Its mechanism of action focuses on blocking the cell cycle in the G1 phase, thereby preventing the division and growth of malignant cells in hormone-sensitive tumors. Palbocent significantly delays disease progression when administered in conjunction with endocrine therapy.

Manufacturer: Incepta Pharmaceuticals Ltd. This medicinal product is a high-quality generic of the innovator drug Ibrance. It is manufactured under strict quality control standards, ensuring full bioequivalence and identical therapeutic efficacy to the brand-name medication.

Key Features:

  • Selective Inhibition: Specifically targets CDK4/6 proteins, which are key drivers of cancer cell proliferation.
  • Endocrine Synergy: Potentiates the efficacy of aromatase inhibitors and fulvestrant.
  • Clinical Evidence: Proven to significantly extend progression-free survival in patients with metastatic breast cancer.

Palbocent is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer:

  • 🔹 In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.
  • 🔹 In combination with fulvestrant in women with disease progression following prior endocrine therapy.

Sales Unit: 1 pack containing 21 capsules, each containing 125 mg of Palbociclib.

⚠️ APPLICATION INSTRUCTIONS:

  • Dosage: The standard dose is 125 mg (one capsule) taken orally once daily for 21 consecutive days, followed by 7 days off treatment (a 28-day cycle).
  • Method: Swallow capsules whole. Must be taken with food to ensure optimal absorption and consistent plasma levels.
  • Consistency: Take the dose at approximately the same time each day.
  • Storage: Store in the original package at a temperature below 30°C in a dry place.
  • Pregnancy and Breastfeeding: Known to cause fetal harm. Strictly contraindicated during pregnancy and nursing.
  • Organ Impairment: Severe hepatic or renal dysfunction.
  • Hypersensitivity to Palbociclib or any of its excipients.
  • Pediatric use (safety and efficacy in children under 18 have not been established).

Professional medical monitoring, including regular blood counts, is required. Potential side effects include:

  • 🩸 Hematologic: Neutropenia (very common), leukopenia, anemia, and thrombocytopenia.
  • 🏃‍♂️ General: Fatigue (asthenia) and physical weakness.
  • 🤢 Gastrointestinal: Nausea, stomatitis, vomiting, and diarrhea.
  • 🦠 Infections: Increased risk of infections due to low white blood cell counts.
  • 💅 Dermatologic: Alopecia (hair thinning) and skin rash.
Active ingredient
Manufacturer
Incepta Pharmaceuticals
Dosage 125 mg
Dosage form Capsules
Capsules per pack 21
100% original product
Delivery across Ukraine
Alternatives

Similar products

Palnat 125 125 mg Natco
View
Natco
125 mg 21 capsule
4385₴ 5043₴
Palbocib 125 mg Aprazer
View
Aprazer
125 mg 21 capsule
3947₴ 4605₴
Palboxen 125 mg Everest
View
Everest
125 mg 21 capsule
21927₴ 24558₴
Palbotiz 100 mg Tizig
View
Tizig
100 mg 21 capsule
10963₴ 12717₴
Reampla 125 125 mg Pfizer
View
Pfizer
125 mg 21 capsule
28505₴ 32890₴
Customer reviews

What Customers Say

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00